Status:
COMPLETED
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Rigshospitalet, Denmark
Aarhus University Hospital
Conditions:
Acromegaly Due to Pituitary Adenoma
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
Detailed Description
Aim: To determine the importance of the GIP system in patients with acromegaly who has paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP antagonist (GIP-A)....
Eligibility Criteria
Inclusion
- Patients under clinical investigation of acromegaly disease with normal kidney function, liver function and hemoglobin levels.
Exclusion
- Medication for acromegaly, adenectomy, liver disease, uncontrolled anemia, severe heart disease, uncontrolled high blood pressure (\>170/100 mmHg), current pregnancy
Key Trial Info
Start Date :
August 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 28 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03807076
Start Date
August 13 2019
End Date
November 28 2023
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biomedical Sciences
Copenhagen, Denmark, 2200